[
  {
    "ts": null,
    "headline": "Baird Q4 2024 International And Global Growth Fund Commentary",
    "summary": "In the fourth quarter of 2024, the Baird Chautauqua International Growth Fund Net Investor Class returned -4.31%, outperforming the MSCI ACWI ex-U.S. IndexÂ® ND, which returned -7.60%.",
    "url": "https://finnhub.io/api/news?id=d6d6283252f961c1956b4e9b204d925bd8cffd09caaa15b4e93b18ba3b17000c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737068100,
      "headline": "Baird Q4 2024 International And Global Growth Fund Commentary",
      "id": 132412293,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163930695/image_1163930695.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "In the fourth quarter of 2024, the Baird Chautauqua International Growth Fund Net Investor Class returned -4.31%, outperforming the MSCI ACWI ex-U.S. IndexÂ® ND, which returned -7.60%.",
      "url": "https://finnhub.io/api/news?id=d6d6283252f961c1956b4e9b204d925bd8cffd09caaa15b4e93b18ba3b17000c"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates",
    "summary": "MRNA and NTLA are down this week after providing financial and strategic updates.",
    "url": "https://finnhub.io/api/news?id=7d82301d9b9fcca0f9cc9ad4e7a3e21da75941e45505b24658a2da5b28052a91",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737046800,
      "headline": "Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates",
      "id": 132439107,
      "image": "https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "MRNA and NTLA are down this week after providing financial and strategic updates.",
      "url": "https://finnhub.io/api/news?id=7d82301d9b9fcca0f9cc9ad4e7a3e21da75941e45505b24658a2da5b28052a91"
    }
  },
  {
    "ts": null,
    "headline": "Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121",
    "summary": "REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS IÂ &Â II. Learn more on RGNX stock here.",
    "url": "https://finnhub.io/api/news?id=ab2df99813f6cc56cf0bd31f5bb520ff65ae23366f744fc671fc4e371aa3989b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737046766,
      "headline": "Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121",
      "id": 132411104,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148124381/image_2148124381.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS IÂ &Â II. Learn more on RGNX stock here.",
      "url": "https://finnhub.io/api/news?id=ab2df99813f6cc56cf0bd31f5bb520ff65ae23366f744fc671fc4e371aa3989b"
    }
  },
  {
    "ts": null,
    "headline": "UBS cuts rating on Regeneron stock amid Eylea uncertainty",
    "summary": "Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to \"Neutral\" from \"Buy\" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.",
    "url": "https://finnhub.io/api/news?id=f894f15e26bc794c7bc6c3b591e722f74527fd7daff56449fe18a7296934c60b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737044910,
      "headline": "UBS cuts rating on Regeneron stock amid Eylea uncertainty",
      "id": 132439108,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to \"Neutral\" from \"Buy\" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.",
      "url": "https://finnhub.io/api/news?id=f894f15e26bc794c7bc6c3b591e722f74527fd7daff56449fe18a7296934c60b"
    }
  },
  {
    "ts": null,
    "headline": "The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN",
    "summary": "NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. . ...",
    "url": "https://finnhub.io/api/news?id=dbc174773acae7eeb82af5ba991e2a74eccb1ad27150f0e711bb236bb6290604",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737006383,
      "headline": "The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN",
      "id": 132404693,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. . ...",
      "url": "https://finnhub.io/api/news?id=dbc174773acae7eeb82af5ba991e2a74eccb1ad27150f0e711bb236bb6290604"
    }
  }
]